2026's most interesting format fight isn't brand vs. brand — it's the workhorse injectable semaglutide against the newest telehealth offering: compounded oral tirzepatide. One has the deepest evidence base in the class; the other trades some certainty for a needle-free life. Here's the honest tale of the tape.
Key Takeaways
- Evidence: injectable semaglutide's weight-loss data is trial-grade and enormous; compounded oral tirzepatide formats lack equivalent published evidence at their compounded doses.
- Convenience: weekly needle vs. daily (or per-schedule) oral — oral wins the needle-averse, loses on routine-dependence.
- Price 2026: injectable sema from $49–$199/mo; compounded oral tirz typically $167–$249/mo.
- Verdict: injectable semaglutide remains the evidence-and-value pick; oral tirzepatide is a legitimate choice specifically for patients who won't inject.
Round 1: Evidence
Injectable semaglutide carries the class's flagship trial program — large randomized trials, published extensions, years of post-market experience at defined doses. Tirzepatide as a molecule has outstanding injectable trial data of its own (its brand trials posted some of the largest average losses in the field). But compounded oral tirzepatide is a pharmacy-formulated format: absorption and effective dosing differ from injection, and there is no comparable body of published outcomes for these specific preparations. That's not an accusation — it's a data asymmetry you should price in. Round to injectable semaglutide, clearly.
Round 2: The Experience
Weekly self-injection sounds worse than it is — modern needles are tiny, and the once-a-week cadence is set-and-forget. Oral formats swap the needle for discipline: consistent timing, often empty-stomach rules, every single day. Needle-phobic patients will happily pay that tax; everyone else tends to find weekly simpler by month three. Round to oral for the needle-averse, injectable for everyone else.
Round 3: Price
| Format | Typical 2026 monthly | Notes |
|---|---|---|
| Injectable semaglutide (compounded) | $49–$199 | Cheapest at annual commitments; the market's price floor |
| Oral tirzepatide (compounded) | $167–$249 | Newer format premium |
| Oral semaglutide tablets (compounded) | $147+ | The budget oral alternative worth remembering |
Round to injectable — and note the third row: if oral is the requirement, oral semaglutide tablets undercut oral tirzepatide meaningfully.
Round 4: Who Should Pick What
- Default patient: injectable semaglutide. Deepest evidence, lowest price, weekly simplicity.
- Truly needle-averse: oral tirzepatide or oral semaglutide — a format you'll actually take beats a format you'll avoid.
- Chasing maximum efficacy with tolerance for needles: injectable tirzepatide is the fourth contender this article isn't about — and often the right answer.
Where to Get Each
Sesame
Compare treatment availability, consultation and membership charges, pharmacy fees and refill policies. Eligibility and medication choice are determined by a clinician.
Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.
Explore Sesame program ↗Affiliate link: we may earn a commission. This is a different provider from the retired program discussed in older comparisons.
MadeMed — Oral Tirzepatide
Oral tirzepatide
One of the only oral tirzepatide formats available by telehealth.
Compounded medications are not FDA-approved.
Wellorithm
Oral tablets — sema $147/mo, tirz $249/mo
Lowest published oral compounded pricing on our tracker.
Compounded medications are not FDA-approved.
Final verdict: Injectable semaglutide by decision — on evidence and price. Oral tirzepatide earns a real place on the card for exactly one audience, and if that's you, it's a fine choice made with open eyes.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.